{"product_id":"pacira-marketing-mix","title":"Pacira Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to a Strategic 4Ps Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003ePacira's marketing success hinges on a carefully orchestrated blend of Product, Price, Place, and Promotion. Discover how their innovative product pipeline, strategic pricing models, targeted distribution, and impactful promotional campaigns create a powerful market presence.\u003c\/p\u003e\n\u003cp\u003eDive deeper into the specifics of Pacira's 4Ps strategy and gain actionable insights that can inform your own business decisions. Unlock the full, professionally written analysis to understand the nuances of their approach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEXPAREL (Bupivacaine Liposome Injectable Suspension)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEXPAREL, Pacira's leading product, is a long-acting local anesthetic designed for postsurgical pain management, administered through infiltration and nerve blocks. Its primary goal is to reduce reliance on opioids, supporting the growing demand for non-opioid pain relief alternatives.\u003c\/p\u003e\n\u003cp\u003eIn 2023, Pacira BioSciences reported EXPAREL net sales of $534.3 million, a 5% increase from the previous year, highlighting its continued market penetration and acceptance. This growth reflects the increasing adoption of non-opioid analgesia in surgical settings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZILRETTA (Triamcinolone Acetonide Extended-Release Injectable Suspension)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZILRETTA, a significant product for Pacira BioSciences, is an extended-release intra-articular injection designed to manage osteoarthritis knee pain. It provides a non-opioid, long-lasting solution, offering relief for up to four months from a single administration.\u003c\/p\u003e\n\u003cp\u003eIn 2023, ZILRETTA generated $262.9 million in net sales, demonstrating its strong market presence and acceptance by healthcare providers and patients seeking alternatives to opioids for chronic knee pain management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eiovera° (Cryoanalgesia Device)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe iovera° system represents a significant product innovation for Pacira BioSciences, offering a drug-free, non-opioid approach to pain management. This handheld device utilizes cryoanalgesia, precisely applying cold to target nerves for immediate and lasting pain relief. This aligns with the growing demand for alternative pain solutions, particularly in the post-pandemic era where opioid concerns remain high.\u003c\/p\u003e\n\u003cp\u003eThis product directly addresses the \"Product\" element of Pacira's 4Ps by diversifying its pain management portfolio beyond its established injectable offerings. The iovera° system provides a novel technological solution, appealing to patients and healthcare providers seeking non-pharmacological options. Its introduction expands Pacira's market reach into areas where traditional drug therapies might be contraindicated or less preferred.\u003c\/p\u003e\n\u003cp\u003eThe market for non-opioid pain management solutions is robust and expanding. For instance, the global nerve ablation market, which includes cryoanalgesia, was valued at approximately $1.5 billion in 2023 and is projected to grow at a CAGR of over 7% through 2030, according to various market research reports. This growth trajectory underscores the market's receptiveness to innovative products like iovera°.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline Innovation (PCRX-201)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePacira's Product strategy is clearly focused on pipeline innovation, exemplified by PCRX-201 (enekinragene inzadenovec). This gene therapy targets the root causes of knee osteoarthritis, signaling a move towards long-term, transformative solutions.  This commitment to addressing underlying disease mechanisms, rather than just symptoms, is a key differentiator.\u003c\/p\u003e\n\u003cp\u003ePCRX-201 represents Pacira's dedication to expanding its therapeutic reach beyond current pain management offerings. By investing in novel gene therapy technology, Pacira aims to capture a significant share of the growing osteoarthritis market, which is projected to reach billions globally by 2030. This forward-looking approach is crucial for sustained growth and market leadership.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Advancement:\u003c\/strong\u003e PCRX-201 is a key asset in Pacira's innovation pipeline.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTherapeutic Focus:\u003c\/strong\u003e Gene therapy for osteoarthritis of the knee, addressing underlying causes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Potential:\u003c\/strong\u003e Targeting a significant segment of the global pain management market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Direction:\u003c\/strong\u003e Demonstrates a commitment to long-term, transformative solutions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpioid-Sparing Focus and Value Proposition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePacira's central value proposition across its entire product line is its commitment to non-opioid pain management, directly addressing the critical public health issue of the opioid crisis. This focus tackles a significant unmet medical need in acute care environments, offering a safer alternative for patients.\u003c\/p\u003e\n\u003cp\u003eThe company's products are designed to enhance patient recovery by delivering extended pain relief without the addictive properties of opioids. This approach not only improves patient outcomes but also aims to reduce the overall burden on healthcare systems by minimizing opioid-related complications and facilitating quicker transitions to home recovery.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eReduced Opioid Consumption:\u003c\/strong\u003e Studies have shown that patients receiving Exparel, a key Pacira product, experience significantly lower opioid use post-surgery compared to those receiving traditional pain management. For example, in certain orthopedic procedures, opioid consumption can be reduced by as much as 50% or more.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImproved Patient Satisfaction:\u003c\/strong\u003e By offering effective pain control with fewer side effects, Pacira's solutions contribute to higher patient satisfaction scores and a better overall surgical experience.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnhanced Recovery and Discharge:\u003c\/strong\u003e The sustained pain relief provided by Pacira's products can lead to earlier mobilization and a smoother transition from hospital to home, potentially shortening hospital stays.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAddressing the Opioid Crisis:\u003c\/strong\u003e With over 100,000 overdose deaths reported annually in the US in recent years, Pacira's opioid-sparing approach offers a vital solution for healthcare providers seeking to mitigate opioid dependence and abuse.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing Non-Opioid Pain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePacira BioSciences' product strategy centers on its innovative non-opioid pain management portfolio. EXPAREL and ZILRETTA are key offerings, providing extended relief for postsurgical and osteoarthritis pain respectively. The iovera° system further diversifies this with a drug-free cryoanalgesia approach. The company is also investing in future solutions like PCRX-201, a gene therapy targeting the root causes of knee osteoarthritis, signaling a commitment to transformative, long-term pain management.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003e2023 Net Sales\u003c\/th\u003e\n\u003cth\u003eKey Benefit\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEXPAREL\u003c\/td\u003e\n\u003ctd\u003eLong-acting local anesthetic for postsurgical pain\u003c\/td\u003e\n\u003ctd\u003e$534.3 million\u003c\/td\u003e\n\u003ctd\u003eReduces opioid reliance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZILRETTA\u003c\/td\u003e\n\u003ctd\u003eExtended-release injection for osteoarthritis knee pain\u003c\/td\u003e\n\u003ctd\u003e$262.9 million\u003c\/td\u003e\n\u003ctd\u003eUp to 4 months of relief from one dose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eiovera° system\u003c\/td\u003e\n\u003ctd\u003eDrug-free cryoanalgesia for pain management\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed\u003c\/td\u003e\n\u003ctd\u003eNon-pharmacological pain relief\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePCRX-201\u003c\/td\u003e\n\u003ctd\u003eGene therapy for knee osteoarthritis\u003c\/td\u003e\n\u003ctd\u003ePre-commercial\u003c\/td\u003e\n\u003ctd\u003eAddresses underlying disease mechanisms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis analysis provides a comprehensive breakdown of Pacira's marketing strategies, examining its Product, Price, Place, and Promotion elements with real-world examples and strategic implications.\u003c\/p\u003e\n\u003cp\u003eIt's designed for professionals seeking a deep understanding of Pacira's market positioning, offering a benchmark against industry best practices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear, concise overview of Pacira's 4Ps marketing strategy, highlighting how each element addresses and alleviates pain points in the healthcare market.\u003c\/p\u003e\n\u003cp\u003eSimplifies complex marketing tactics into an actionable framework, demonstrating Pacira's commitment to pain relief across its product and service offerings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales to Healthcare Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira BioSciences, Inc. primarily employs a direct sales strategy to reach healthcare facilities. This includes hospitals, ambulatory surgical centers (ASCs), and various other acute care environments. This focused distribution ensures their pain management solutions, such as EXPAREL, are readily available in settings where effective postsurgical pain control is paramount.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Group Purchasing Organization (GPO) Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira BioSciences actively partners with major Group Purchasing Organizations (GPOs) like Premier, Inc., a significant move that unlocks access to a substantial portion of the U.S. hospital market.  These strategic alliances are crucial for extending the reach of their pain management solutions, including EXPAREL.  In 2023, Premier reported serving over 4,400 U.S. hospitals and health systems, highlighting the immense network Pacira can tap into through such collaborations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Wholesalers and Specialty Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePacira relies on a sophisticated network of pharmaceutical wholesalers and specialty distributors to ensure its temperature-sensitive products reach their destinations safely and efficiently. This strategy is vital for maintaining the integrity of their offerings, particularly for products like EXPAREL, which require precise temperature control throughout the supply chain.\u003c\/p\u003e\n\u003cp\u003eIn 2024, the pharmaceutical distribution market is projected to reach over $1.7 trillion globally, highlighting the critical role these intermediaries play. Pacira's engagement with these partners ensures broad market access and reliable inventory management, a key component of their product strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Outpatient and Office Settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePacira is strategically leveraging the NOPAIN Act, effective January 2025, to broaden EXPAREL's reach into outpatient and office-based surgical settings. This legislative shift establishes dedicated Medicare reimbursement, a crucial factor in boosting adoption. \u003c\/p\u003e\n\u003cp\u003eThe introduction of a new product-specific J-code for EXPAREL further solidifies its accessibility and financial viability in these evolving care environments. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eNOPAIN Act Implementation:\u003c\/strong\u003e January 2025\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKey Driver:\u003c\/strong\u003e Separate Medicare reimbursement pathways\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImpact:\u003c\/strong\u003e Increased patient access in outpatient and office settings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted Market Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePacira's marketing strategy zeroes in on specific medical fields to maximize product impact. They concentrate on anesthesiology, orthopedics, pain management, and oral and maxillofacial surgery, ensuring their offerings reach the right healthcare professionals and patients. This focused distribution is crucial for their product relevance and adoption within these specialties.\u003c\/p\u003e\n\u003cp\u003eThis targeted approach is evident in their sales force deployment and marketing communications. For instance, in 2023, Pacira reported that its EXPAREL product, a non-opioid analgesic, saw significant uptake in orthopedic surgical procedures, a key focus area. The company's efforts are designed to align product availability with the procedural volumes and prescribing habits within these targeted segments.\u003c\/p\u003e\n\u003cp\u003eKey market segments for Pacira include:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAnesthesiology:\u003c\/strong\u003e Focusing on perioperative pain management solutions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrthopedics:\u003c\/strong\u003e Targeting post-surgical pain control in joint replacement and other orthopedic procedures.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePain Management:\u003c\/strong\u003e Addressing chronic and acute pain conditions with innovative therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOral and Maxillofacial Surgery:\u003c\/strong\u003e Providing solutions for pain following dental and reconstructive surgeries.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlace Strategy: Broadening Access \u0026amp; Future Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePacira's place strategy emphasizes direct sales to hospitals and ambulatory surgical centers, ensuring their pain management solutions are available where needed most. They also leverage partnerships with major Group Purchasing Organizations (GPOs), like Premier, Inc., which in 2023 served over 4,400 U.S. hospitals, significantly expanding their market reach for products like EXPAREL.\u003c\/p\u003e\n\u003cp\u003eThe company further utilizes a robust network of pharmaceutical wholesalers and specialty distributors to maintain product integrity, especially for temperature-sensitive items. This distribution infrastructure is critical in a global pharmaceutical distribution market projected to exceed $1.7 trillion in 2024.\u003c\/p\u003e\n\u003cp\u003ePacira is strategically positioned to benefit from the NOPAIN Act, effective January 2025, which will facilitate EXPAREL's access to outpatient and office-based settings through dedicated Medicare reimbursement, further enhanced by a new product-specific J-code.\u003c\/p\u003e\n\u003cp\u003eTheir marketing efforts are concentrated on key specialties such as anesthesiology, orthopedics, pain management, and oral and maxillofacial surgery, aligning product availability with procedural volumes and prescribing habits, as seen with EXPAREL's uptake in orthopedic procedures in 2023.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDistribution Channel\u003c\/th\u003e\n\u003cth\u003eKey Partners\/Initiatives\u003c\/th\u003e\n\u003cth\u003e2023\/2024\/2025 Relevance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Sales\u003c\/td\u003e\n\u003ctd\u003eHospitals, ASCs\u003c\/td\u003e\n\u003ctd\u003eEnsures availability in acute care settings.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO Partnerships\u003c\/td\u003e\n\u003ctd\u003ePremier, Inc. (serves \u0026gt;4,400 U.S. hospitals in 2023)\u003c\/td\u003e\n\u003ctd\u003eExpands access to a large hospital network.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\/Distributors\u003c\/td\u003e\n\u003ctd\u003eSpecialty distributors for temperature-sensitive products\u003c\/td\u003e\n\u003ctd\u003eMaintains product integrity; supports a global distribution market \u0026gt;$1.7T in 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegislative\/Reimbursement\u003c\/td\u003e\n\u003ctd\u003eNOPAIN Act (effective Jan 2025), EXPAREL J-code\u003c\/td\u003e\n\u003ctd\u003eEnables outpatient\/office-based setting access and financial viability.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003ePacira 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual document you’ll receive instantly after purchase—no surprises. This comprehensive Pacira 4P's Marketing Mix Analysis covers Product, Price, Place, and Promotion in detail. You'll gain immediate access to this fully complete, ready-to-use analysis upon completing your purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55538767036793,"sku":"pacira-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/pacira-marketing-mix.png?v=1753624810","url":"https:\/\/portersfiveforce.com\/products\/pacira-marketing-mix","provider":"Porter's Five Forces","version":"1.0","type":"link"}